Table 2

Event rate at long term follow up, number needed to treat, and events avoided per 1000 patients treated in randomised clinical trials comparing primary angioplasty and fibrinolysis

Long term eventsPTCA (%)Lysis (%)p ValueOdds ratio (95% CI)ARRNNTNEA × 1000
*Data on 2635 patients. Presented at the American Heart Association meeting in Atlanta, October 1999.
†The SHOCK trial did not compare PTCA with lysis, but a strategy of emergency revascularisation versus initial medical stabilisation.
‡Includes disabling stroke.
For explanation of abbreviations see table 1.
Mortality
    Weaver 6 months* 6.1 8.1 0.0550.73 (0.52 to 0.98) 25020/1000
    PAMI 2 yearsw29 6.2 9.5 0.21Not available 3.33033/1000
    Zijlstra 5±2 years1613.423.9 0.010.54 (0.36 to 0.87)10.510100/1000
    SHOCK 6 months850.363.1 0.0270.80 (0.65 to 0.95)12.88125/1000
    SHOCK 1 year†5570 0.008Not available157143/1000
    C-PORT 6 monthsw46 6.2 7.1 0.72Not available 0.91119/1000
Reinfarction
    Weaver 6 months 4.4 9.7 0.00010.43 (0.3 to 0.6) 5.31953/1000
    PAMI 2 years10.816.0 0.01Not available 5.21953/1000
    Zijlstra 5±2 years 622 0.00010.27 (0.15 to 0.52) 66167/1000
    C-PORT 6 months 5.310.6 0.04Not available 5.31953/1000
Mortality or non-fatal reinfarction
    Weaver 6 months 6.813.4 0.00010.47 (0.43 to 0.7) 6.61567/1000
    PAMI 2 years14.923 0.034Not available 8.11283/1000
    Zijlstra 5±2 years2246 0.00010.13 (0.43 to 0.91)244250/1000
    C-PORT 6 months‡12.419.9 0.030.57 (0.34 to 0.95) 7.51377/1000
New revascularisation
    PAMI 2 years32.854 0.001Not available21.25200/1000
    Zijlstra 5±2 years46.471.1<0.001Not available24.74300/1000
Recurrence of ischaemia
    PAMI 2 years36.448 0.026Not available11.69111/1000
    Zijlstra 5±2 years5289.5<0.001Not available37.53333/1000